Ibandronsäure Stada

Active Ingredient:: Ibandronic Acid
Origin:: EU

Ibandronsäure Stada (Ibandronic Acid)

Q: What is Ibandronsäure Stada used for?

Ibandronsäure Stada contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis and Paget's disease of bone. It works by reducing bone resorption, thereby helping to strengthen bone and lower the risk of fractures in these conditions.

Q: How does ibandronic acid work?

Ibandronic acid binds to hydroxyapatite at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is taken up and interferes with the mevalonate pathway, leading to osteoclast apoptosis and a marked decrease in bone resorption.

Q: What is the usual dose of Ibandronsäure Stada?

The dose and infusion schedule of Ibandronsäure Stada are determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment guidelines. Patients should follow the specific instructions provided by their healthcare professional.

Q: Is Ibandronsäure Stada safe during pregnancy or breastfeeding?

Safety of ibandronic acid in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Q: How do I order Ibandronsäure Stada from GNH India?

To request Ibandronsäure Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Q: How does Ibandronsäure Stada compare with other bisphosphonates?

Ibandronic acid is a potent, nitrogen‑containing bisphosphonate with a long skeletal retention time, allowing less frequent dosing compared with some alternatives such as alendronate. Its efficacy in reducing vertebral and hip fractures is comparable, while the safety profile is similar, emphasizing renal monitoring and management of acute‑phase reactions.

Q: What are the storage and handling requirements for Ibandronsäure Stada?

Ibandronsäure Stada should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Q: How is Ibandronsäure Stada administered?

The medication is supplied as an intravenous solution and is administered by a qualified healthcare professional via slow IV infusion. The infusion rate and duration are specified in the prescribing information to minimise infusion‑related reactions.

Q: What are the most serious risks associated with Ibandronsäure Stada?

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Q: Who should not use Ibandronsäure Stada?

Ibandronsäure Stada is contraindicated in patients with known hypersensitivity to ibandronic acid or any component of the formulation, in those with severe renal impairment (eGFR <30 mL/min), and in individuals with untreated hypocalcemia. It should also be used with caution in pregnant or breastfeeding women.

Ibandronic acid, the active ingredient in Ibandronsäure Stada, is a bisphosphonate presented as an intravenous solution for intravenous use. It treats osteoporosis and Paget's disease of bone in adults.

GNH India supplies Ibandronsäure Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stadapharm Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronic acid is a bisphosphonate that inhibits bone resorption and is indicated for the following conditions:

Osteoporosis: reduces the risk of vertebral and hip fractures by decreasing bone turnover.
Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain.

How It Works

Ibandronic acid binds avidly to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is internalized, disrupting the mevalonate pathway, which leads to osteoclast apoptosis and a consequent reduction in bone resorption.

Side Effects

Ibandronic acid may cause a range of adverse reactions. The most frequently reported events are generally mild and transient.

Common Side Effects

Acute‑phase reaction: fever, chills, myalgia, and headache.
Nausea or vomiting.
Transient flu‑like symptoms.
Infusion site discomfort or pain.
Transient low calcium levels.
Mild rash.

Serious or Rare Side Effects

Osteonecrosis of the jaw.
Atypical femur fracture.
Severe renal impairment or acute kidney injury.
Anaphylactic or severe hypersensitivity reactions.

Precautions & Warnings

Before initiating therapy with Ibandronic acid, several safety considerations should be observed.

Renal function: assess baseline creatinine clearance and avoid use in severe renal impairment.
Calcium status: correct hypocalcemia and ensure adequate vitamin D levels prior to infusion.
Concomitant nephrotoxic drugs: avoid or monitor closely to reduce renal risk.
Pregnancy and lactation: use only if the potential benefit justifies the potential risk; safety data are limited.
Infusion rate: administer according to prescribing information to minimise acute‑phase reactions.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ibandronic acid can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

Concurrent bisphosphonate therapy: may cause excessive suppression of bone turnover.
Severe renal impairment (eGFR <30 mL/min): heightened risk of nephrotoxicity.
Existing hypocalcemia: can worsen low calcium levels.
Live vaccines: may increase susceptibility to infection.

Moderate Interactions (Monitor Closely)

NSAIDs: may compound renal stress.
Aminoglycoside antibiotics: potential additive nephrotoxicity.
Loop diuretics: may affect calcium balance and increase risk of hypocalcemia.

Frequently Asked Questions

Ibandronsäure Stada contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis and Paget's disease of bone. It works by reducing bone resorption, thereby helping to strengthen bone and lower the risk of fractures in these conditions.

Ibandronic acid binds to hydroxyapatite at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is taken up and interferes with the mevalonate pathway, leading to osteoclast apoptosis and a marked decrease in bone resorption.

The dose and infusion schedule of Ibandronsäure Stada are determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment guidelines. Patients should follow the specific instructions provided by their healthcare professional.

Safety of ibandronic acid in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Ibandronsäure Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ibandronic acid is a potent, nitrogen‑containing bisphosphonate with a long skeletal retention time, allowing less frequent dosing compared with some alternatives such as alendronate. Its efficacy in reducing vertebral and hip fractures is comparable, while the safety profile is similar, emphasizing renal monitoring and management of acute‑phase reactions.

Ibandronsäure Stada should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

The medication is supplied as an intravenous solution and is administered by a qualified healthcare professional via slow IV infusion. The infusion rate and duration are specified in the prescribing information to minimise infusion‑related reactions.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Ibandronsäure Stada is contraindicated in patients with known hypersensitivity to ibandronic acid or any component of the formulation, in those with severe renal impairment (eGFR <30 mL/min), and in individuals with untreated hypocalcemia. It should also be used with caution in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.